Selective drug combination vulnerabilities in STAT3- and TP53-mutant malignant NK cells

E Parri; H Kuusanmaki; D Bulanova; S Mustjoki; K Wennerberg

doi:10.1182/bloodadvances.2020003300

Selective drug combination vulnerabilities in STAT3- and TP53-mutant malignant NK cells

E Parri, H Kuusanmaki, D Bulanova, S Mustjoki, K Wennerberg

Forskningsoutput: Tidskriftsbidrag › Artikel › Vetenskaplig › Peer review

Originalspråk	engelska
Tidskrift	Blood advances
Volym	5
Nummer	7
Sidor (från-till)	1862-1875
Antal sidor	14
ISSN	2473-9529
DOI	https://doi.org/10.1182/bloodadvances.2020003300
Status	Publicerad - 13 apr. 2021
MoE-publikationstyp	A1 Tidskriftsartikel-refererad

Vetenskapsgrenar

3122 Cancersjukdomar

Åtkomst av dokument

10.1182/bloodadvances.2020003300

Selective drug combination vulnerabilities in STAT3- and TP53-mutant malignant NK cellsSlutlig publicerad version, 1,56 MBLicens: CC BY

Citera det här

@article{b3ce9c24856d4d18bb70d84032c62462,

title = "Selective drug combination vulnerabilities in STAT3- and TP53-mutant malignant NK cells",

keywords = "MYCOPLASMA-FERMENTANS, LINE, INHIBITION, LYMPHOMA, RESISTANCE, MUTATIONS, GLUCOCORTICOIDS, PEMBROLIZUMAB, RUXOLITINIB, EXPRESSION, 3122 Cancers",

author = "E Parri and H Kuusanmaki and D Bulanova and S Mustjoki and K Wennerberg",

year = "2021",

month = apr,

day = "13",

doi = "10.1182/bloodadvances.2020003300",

language = "English",

volume = "5",

pages = "1862--1875",

journal = "Blood advances",

issn = "2473-9529",

publisher = "American Society of Hematology",

number = "7",

}

TY - JOUR

T1 - Selective drug combination vulnerabilities in STAT3- and TP53-mutant malignant NK cells

AU - Parri, E

AU - Kuusanmaki, H

AU - Bulanova, D

AU - Mustjoki, S

AU - Wennerberg, K

PY - 2021/4/13

Y1 - 2021/4/13

KW - MYCOPLASMA-FERMENTANS

KW - LINE

KW - INHIBITION

KW - LYMPHOMA

KW - RESISTANCE

KW - MUTATIONS

KW - GLUCOCORTICOIDS

KW - PEMBROLIZUMAB

KW - RUXOLITINIB

KW - EXPRESSION

KW - 3122 Cancers

U2 - 10.1182/bloodadvances.2020003300

DO - 10.1182/bloodadvances.2020003300

M3 - Article

VL - 5

SP - 1862

EP - 1875

JO - Blood advances

JF - Blood advances

SN - 2473-9529

IS - 7

ER -